blue cross blue shield semaglutide coverage Drops of GLP-1 Obesity Drugs Blue Cross Blue Shield of

A Breakthrough Award, New Evidence in Parkinson's and Heart Disease

Retatrutide is a research peptide studied in metabolic research peptides

Learn why some patients experience cramping on semaglutide or tirzepatide, the indirect mechanisms involved, and evidence-based strategies to prevent and manage muscle symptoms during GLP-1 therapy.

Learn what triggers them and how to cope.

A significant wave of patent and data protection expires in 2026 across eight key markets in wave 1: Canada, Brazil, China, India, Mexico , Turkey, Saudi Arabia* and South Africa (see Figure 1)

Circana highlighted opportunities for brands to align with GLP-1 users goals.